TRPS1's role in boosting antitumor immunity by stabilizing regulatory T cells
Official title: Elucidating roles of TRPS1 in regulating antitumor immunity
Funded at Mayo Clinic Arizona · NIH-11337416 · Data updated 2026-11-12
This NIH grant aims to understand how TRPS1 helps regulatory T cells work in tumors, with the goal of making cancer immunotherapy more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $657,698 |
| NIH project number | 1R01CA311117-01 |
| Project ID | NIH-11337416 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with cancers where tumor-infiltrating regulatory T cells contribute to disease progression and immunotherapy resistance.
✕Less likely to help
Patients without tumors where Treg-mediated suppression is not a factor may not benefit directly.
What this research studies
Researchers at Mayo Clinic Arizona will study how the transcription factor TRPS1 influences regulatory T cells in cancer, using advanced genetic tools and multi-omic approaches. They will examine how TRPS1 affects Treg phenotype, their function, and stability within tumors, and how this impacts responses to immunotherapy. The project builds on early findings showing TRPS1 can drive Tregs to a tumor-friendly state and that TRPS1 loss can slow tumor growth in models. By mapping molecular pathways and identifying key regulators like BATF and BLIMP-1, the work aims to uncover targets to overcome tumor-induced immunosuppression.
Why it matters
Potential benefit: If successful, the research could reveal new targets to enhance cancer immunotherapy by modulating Treg activity in tumors.
How similar studies have gone: Previous studies show that modulating Treg stability can affect tumor growth and immune responses, supporting this approach as promising but still exploratory.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Ager, Casey — Mayo Clinic Arizona
- Study coordinator: Ager, Casey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.